Skip to search formSkip to main contentSkip to account menu

SOM-230

Known as: SOM 230, SOM230 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

pasireotide

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2012
Highly Cited
2012
Pasireotide (SOM230) shows efficacy and tolerability in the treatment of patients with advanced neuroendocrine tumors refractory or resistant to octreotide LAR: results from a phase II study.
Pasireotide (SOM230) is a novel multireceptor-targeted somatostatin (sst) analog with high binding affinity for sst receptor… 
Review
2012
Review
2012
Clinical review: Current scientific rationale for the use of somatostatin analogs and mTOR inhibitors in neuroendocrine tumor therapy.
CONTEXT Among the innovative molecules used to manage neuroendocrine tumors, there is growing interest in combining the… 
Highly Cited
2010
Highly Cited
2010
Pasireotide and octreotide stimulate distinct patterns of sst2A somatostatin receptor phosphorylation.
Pasireotide (SOM230) is currently under clinical evaluation as a successor compound to octreotide for the treatment of acromegaly… 
Highly Cited
2010
Highly Cited
2010
Effect of everolimus on cell viability in nonfunctioning pituitary adenomas.
CONTEXT Pituitary adenomas can cause specific syndromes due to hormone excess and/or determine sellar mass symptoms. Pituitary… 
Highly Cited
2006
Highly Cited
2006
The effects of SOM230 on cell proliferation and adrenocorticotropin secretion in human corticotroph pituitary adenomas.
CONTEXT There is no tumor-directed medical therapy available for Cushing's disease. OBJECTIVE The objective was to determine… 
Highly Cited
2006
Highly Cited
2006
Somatostatin analogues stimulate p27 expression and inhibit the MAP kinase pathway in pituitary tumours.
OBJECTIVES Somatostatin (SST) analogues play an important role in the medical management of somatotroph pituitary adenomas and… 
Highly Cited
2005
Highly Cited
2005
Distinct functional properties of native somatostatin receptor subtype 5 compared with subtype 2 in the regulation of ACTH release by corticotroph tumor cells.
In a series of human corticotroph adenomas, we recently found predominant mRNA expression of somatostatin (SS) receptor subtype 5… 
Highly Cited
2004
Highly Cited
2004
A single-dose comparison of the acute effects between the new somatostatin analog SOM230 and octreotide in acromegalic patients.
Treatment with the somatostatin receptor (sst) subtype 2 predominant analogs octreotide and lanreotide induces clinical and… 
Highly Cited
2003
Highly Cited
2003
A novel somatostatin mimic with broad somatotropin release inhibitory factor receptor binding and superior therapeutic potential.
A rational drug design approach, capitalizing on structure-activity relationships and involving transposition of functional… 
Highly Cited
2002
Highly Cited
2002
SOM230: a new somatostatin peptidomimetic with potent inhibitory effects on the growth hormone/insulin-like growth factor-I axis in rats, primates, and dogs.
The goal of this project was to find a somatostatin (SRIF) analog with superior therapeutic potential. Receptor binding studies… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)